Skip to content
Open access

ZBTB10 inhibits ccRCC progression by epigenetically silencing GPX4 through a self-regulatory ZBTB10/DNMT1/FBXW4 loop

Sep 2026 · Cell Death & Disease · 0 citations

TL;DR

ZBTB10 is identified as a suppressor of ccRCC progression that transcriptionally represses GPX4, a central inhibitor of ferroptosis and an epigenetic mechanism linking ZBTB10 to ferroptosis in ccRCC is revealed and targeting the ZBTB10/DNMT1/FBXW4/GPX4 axis may provide a therapeutic strategy for limiting ccRCC progression.

Abstract

Clear cell renal cell carcinoma (ccRCC) is a common urological malignancy with limited therapeutic options for advanced disease. Aberrant DNA methylation and dysregulated ferroptosis have both been implicated in ccRCC progression, yet the mechanisms connecting these processes remain incompletely defined. Here, we identify ZBTB10 as a suppressor of ccRCC progression that transcriptionally represses GPX4, a central inhibitor of ferroptosis. Mechanistically, ZBTB10 recruits DNMT1 to the GPX4 promoter, thereby increasing promoter methylation and silencing GPX4 expression. We further define a self-regulatory ZBTB10/DNMT1/FBXW4 loop that maintains this epigenetic state. FBXW4 acts as an E3 ubiquitin ligase that promotes DNMT1 degradation and directly ubiquitinates ZBTB10 to reduce its stability. In turn, ZBTB10 recruits DNMT1 to the FBXW4 promoter, increases promoter methylation, and suppresses FBXW4 transcription. This self-regulatory circuit stabilizes both ZBTB10 and DNMT1, sustains low GPX4 expression, and promotes ferroptosis in ccRCC cells, as evidenced by increased lipid peroxidation and reactive oxygen species accumulation. Together, these findings reveal an epigenetic mechanism linking ZBTB10 to ferroptosis in ccRCC and suggest that targeting the ZBTB10/DNMT1/FBXW4/GPX4 axis may provide a therapeutic strategy for limiting ccRCC progression.

Read PDF

Similar papers

Open access Sep 2026

ZEB1 directly activates IL-6 to promote triple-negative breast cancer stemness in an epigenetically constrained context

ZEB1 is a key driver of breast cancer pathogenesis and therapy resistance, largely through its ability to promote cancer stem cells (CSCs). Although tumor-secreted cytokines such as IL-6 are known to support tumor progression, how their expression is regulated by upstream transcriptional factors such as ZEB1 remains in...

Wei-Yue Zhang, Yifan Zhou, Wei Ma et al. · 0 citations
Open access Aug 2026

Decitabine suppresses triple-negative breast cancer by disrupting DNMT1 liquid-liquid phase separation and synergizes with G9a inhibition

Triple-negative breast cancer (TNBC) remains a substantial clinical challenge due to the lack of well-defined therapeutic targets. Previous studies have demonstrated that epigenetic modifiers play crucial roles in the progression of various cancers. In this study, we identify DNA methyltransferase 1 (DNMT1) as a critic...

Mei-Lin Hu, Hao-Jie Peng, Guo-Chang Qiu et al. · 0 citations
Open access Sep 2026

KDM4B-mediated AP2A1-K217 demethylation promotes immune evasion and anti-PD-1 therapy resistance in renal cell carcinoma

The role of non-histone lysine methylation in tumorigenesis has attracted increasing attention, and the dysregulated “writers”, “erasers” and “readers” of it are promising therapeutic targets. In this study, we demonstrated that lysine-specific demethylase 4B (KDM4B) was significantly upregulated in renal cell carc...

Zi-Ran Dai, Ming-Xiao Zhang, Hao Zhou et al. · 0 citations
Sep 2026

PRMT1 and YBX1 Cooperatively Transcriptionally Activate GPX4 to Inhibit Ferroptosis and Promote Breast Cancer Progression.

Ferroptosis, a regulated form of cell death driven by lipid peroxide accumulation, is crucial in tumor development and controlled by Glutathione Peroxidase 4 (GPX4). Targeting ferroptosis offers a promising cancer therapy approach but remains challenging. Here we show that Protein Arginine Methyltransferase 1 (PRMT1) i...

Yu Li, Bao-Wen Yuan, Jia-Xiang Liu et al. · 0 citations
Open access Aug 2026

Reversing KDM6A phosphorylation-driven epigenetic suppression restores pyroptosis and synergizes with anti-PD-1 therapy in HNSCC

Immune checkpoint blockade (ICB) has revolutionized head and neck squamous cell carcinoma (HNSCC) treatment. Yet, a major barrier to response is that tumor cells are epigenetically reprogrammed to resist immunogenic cell death, particularly pyroptosis. To elucidate how tumor cells are pre-conFigured for pyroptosis...

Yi-Kang Ji, Xin-Ran Zhao, Cheng Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.